المؤلفون: M. Korokin V., V. Soldatov O., A. Tietze A., M. Golubev V., A. Belykh E., M. Kubekina V., O. Puchenkova A., T. Denisyuk A., V. Gureyev V., T. Pokrovskaya G., O. Gudyrev S., M. Zhuchenko A., M. Zatolokina A., M. Pokrovskiy V., М. Корокин B., В. Солдатов О., А. Титце, И. Голубев В., А. Белых Е., М. Кубекина В., О. Пученкова А., Т. Денисюк А., В. Гуреев В., Т. Покровская Г., О. Гудырев С., М. Жученко А., М. Затолокина А., М. Покровский В.

المساهمون: Работа выполняется при поддержке Минобрнауки России. Соглашение о субсидии № 05.605.21.0109 (уникальный идентификатор соглашения RFMEFI60519X0191).

المصدر: Pharmacy & Pharmacology; Том 7, № 6 (2019); 312-320 ; Фармация и фармакология; Том 7, № 6 (2019); 312-320 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2019-7-6

مصطلحات موضوعية: atherosclerosis, erythropoietin, rats, P-αB, cibenitide, endothelium, атеросклероз, эритропоэтин, крысы, цибенитид, эндотелий

وصف الملف: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/550/581; https://www.pharmpharm.ru/jour/article/view/550/580; Глушко А.А., Воронков А.В., Черников М.В. Молекулярные мишени для поиска веществ, обладающих эндотелиопротекторными свойствами (обзорная статья) // Биоорганическая химия. 2014. Т. 40. № 5. С. 515–527. DOI:10.7868/S0132342314050066.; Тюренков И.Н., Воронков А.В., Слиецанс А.А., Волотова Е. В. Эндотелиопротекторы новый класс фармакологических препаратов // Вестник Российской академии медицинских наук. 2012, Т. 67, №7. – С. 50–57. DOI: https://doi.org/10.15690/vramn.v67i7.341; Zárate A., Manuel-Apolinar L., Basurto L., De la Chesnaye E., Saldívar I. Cholesterol and atherosclerosis. Historical considerations and treatment // Arch Cardiol Mex. – 2016. – V. 86, N 2. – P. 163–9. doi:10.1016/j.acmx.2015.12.002. Epub 2016 Jan 7.; Orekhov A.N., Poznyak A.V., Sobenin I.A., Nikifirov N.N., Ivanova E.A. Mitochondrion as a selective target for treatment of atherosclerosis: Role of mitochondrial DNA mutations and defective mitophagy in the pathogenesis of atherosclerosis and chronic inflammation // Curr Neuropharmacol. 2019. doi:10.2174/1570159X17666191118125018. [Epub ahead of print].; Marzetti E., Calvani R., Cesari M., Buford T.W., Lorenzi M., Behnke B.J., Leeuwenburgh C. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials // Int J Biochem Cell Biol. – 2013. – V. 45, N 10. – P. 2288–301. doi:10.1016/j.biocel.2013.06.024.; Воронков А. В., Поздняков Д. И., Мирошниченко К. А., Потапова А. А. Влияние новых производных пиримидина на вазодилатирующую функцию эндотелия сосудов головного мозга в условиях хронической травматической энцефалопатии // Экспериментальная и клиническая фармакология. 2019. Т. 82. № 11. С. 11–14. DOI:10.30906/0869-2092-2019-82-11-11-14.; Воронков А.В., Поздняков Д.И. Оценка влияния 4-гидрокси-3,5-ди-трет-бутилкоричной кислоты на изменения антитромботического потенциала эндотелия у кроликов в условиях ишемии головного мозга // Экспериментальная и клиническая фармакология. 2018. Т. 81. № 8. С. 3–7. DOI:10.30906/0869-2092-2018-81-8-3-7; Gimbrone M.A. Jr., García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis // Circ Res. – 2016. – V. 118, N 4. – P. 620–636. doi:10.1161/CIRCRESAHA.115.306301.; Елагин, В.В. Подходы к коррекции ишемических и реперфузионных повреждений почек в эксперименте / В.В. Елагин, О.И. Братчиков, А.А. Ульянова // Научные результаты биомедицинских исследований. – 2018. – №4(3). – С. 63–69. doi:10.18413/2313-89552018-4-3-0-6.; Shabelnikova A.S., Lutsenko V.D., Pokrovskii M.V., Peresipkina A.A., Korokin M.V., Gudyrev O.S., Hoshenko Y.A. Protective effects of recombinant erythropoietin in ischemia of the retina: The role of mechanisms of preconditioning // Research Journal of Medical Sciences. – 2015. – V. 9, N 4. – P. 200–203. doi:10.3923/rjmsci.2015.200.203.; Корокина, Л.В. Фармакологическая коррекция L-NAME индуцированного дефицита оксида азота рекомбинантным эритропоэтином / Л.В. Корокина, И.М. Колесник, M.В. Покровский, М.В. Корокин, А.С. Белоус, Е.Б. Артюшкова, Т.Г. Покровская, О.С. Гудырев, А.Е. Королев, Л.А. Павлова, О.О. Новиков // Кубанский научный медицинский вестник. – 2009. – №9 (114). – С. 66–69.; Denisyuk T. Pharmacotherapeutic strategies for endothelial dysfunction correction with use of statins in syndrome of systemic inflammatory response // Research Results in Pharmacology. – 2017. – V. 3, N 4. – P. 35–77. doi:10.18413/2313-8971-2017-3-4-35-77.; Денисюк, Т.А. Сочетанное применение рекомбинатного эритропоэтина и статинов при эндотоксининдуцированной эндотелиальной дисфункции / Т.А. Денисюк, М.В. Покровский // Аллергология и иммунология. – 2016. – №17(1). – С. 64–65.; Rajkumar D.S.R., Gudyrev O.S., Faiteison A.V., Pokrovskii M.V. Study of the microcirculation level in bone with osteoporosis and osteoporotic fractures during therapy with recombinant erythropoietin, rosuvastatin and their combinations // Research result: pharmacology and clinical pharmacology. –2015. – V. 4, N 6. – P. 57–60. doi:10.18413/2313-8971-2015-1-4-57-60.; Souvenir R., Doycheva D., Zhang J.H., Tang J. Erythropoietin in stroke therapy: friend or foe // Curr Med Chem. – 2015. – V. 22, N 10. – P. 1205–13.; Pearl R.G. Erythropoietin and organ protecttion: lessons from negative clinical trials // Crit Care. –2014. – V. 18, N 5. – P. 526. doi:10.1186/s13054-014-0526-9.; Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor // Proc Natl Acad Sci U S A. –2004. – V. 101, N 41. – P. 14907–12. doi.org/10.1073/pnas.0406491101.; Brines M., Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin // Proc Natl Acad Sci USA. – 2008. – V. 105, N 31. – P. 10925–30. doi:10.1073/pnas.0805594105.; Sultan F., Singh T.U., Kumar T., Rungsung S., Rabha D.J., Vishwakarma A., Sukumaran S.V., Kandasamy A., Parida S. Shortterm exposure of erythropoietin impairs endothelial function through inhibition of nitric oxide production and eNOS mRNA expression in the rat pulmonary artery // Pharmacol Rep. –2017. – V. 69, N 4. – P. 658–665. doi:10.1016/j.pharep.2017.02.003.; Pytela R., Pierschbacher M.D., Ginsberg M.H., Plow E.F., Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors // Science. –1986. – V. 231, N 4745. – P. 1559–62. doi:10.1126/science.2420006.; Sheu J.R., Yen M.H., Peng H.C., Chang M.C., Huang T.F. Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments // Eur J Pharmacol. –1995. – V. 294, N 1. – P. 231–8. doi:10.1016/0014-2999(95)00530-7.; Hung Y.C., Kuo Y.J., Huang S.S., Huang T.F. Trimucrin, an Arg-Gly-Asp containing disintegrin, attenuates myocardial ischemia-reperfusion injury in murine by inhibiting platelet function // Eur J Pharmacol. – 2017. – V. 813. – P. 24–32. doi:10.1016/j.ejphar.2017.07.039.; Pastorova V.E., Liapina L.A., Alshmarin I.P., Ostrovskaia P.U., Gudasheva T.A., Lugovskoĭ E.V. Fibrin-depolymerization activity and the antiplatelet effect of small cyclic and linear proline-containing peptides // Izv Akad Nauk Ser Biol. – 2001. – N. 5. – P. 593–6.; Lyapina L.A., Pastorova V.E., Obergan T.Y. Changes in hemostatic parameters after intranasal administration of peptide Pro-GlyPro // Bull Exp Biol Med. –2007. – V. 144, N 4. – P. 491–3. doi:10.1007/s10517-007-0358-6.; Liapina L.A., Grigor’eva M.E., Andreeva L.A., Miasoedov N.F. Protective antithrombotic effects of proline-containing peptides in the animal body subjected to stress // Izv Akad Nauk Ser Biol. –2010. – N 4. – P. 462–7.; Shevchenko K.V., Nagaev I.Y., Andreeva L.A., Shevchenko V.P., Myasoedov N.F. Stability of prolin-containing peptides in biological media // Biomed Khim. – 2019. – V. 65, N 3. – P. 180– 201. doi:10.18097/PBMC20196503180.; Wang Z., Zhang S., Jin H., Wang W., Huo J., Zhou L., Wang Y., Feng F., Zhang L. Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based pharmacophore generation // Eur J Med Chem. – 2011. – V. 46, N 8. – P. 3428–33. doi:10.1016/j. ejmech.2011.05.007.; Montezano A.C., Nguyen Dinh Cat A., Rios F.J., Touyz R.M. Angiotensin II and vascular injury // Curr Hypertens Rep. –2014. – V. 16, N 6. – P. 431. doi:10.1007/s11906-014-0431-2.; https://www.pharmpharm.ru/jour/article/view/550

الاتاحة: https://www.pharmpharm.ru/jour/article/view/550
https://doi.org/10.19163/2307-9266-2019-7-6-312-320

المؤلفون: A. Lila M., V. Mazurov I., E. Zonova V., O. Nesmeyanova B., T. Plaksina V., D. Krechikova G., O. Reshet’ko V., L. Denisov N., I. Gordeev G., T. Pokrovskaya G., O. Antipova V., T. Kropotina V., T. Povarova V., P. Shesternya A., E. Ushakova N., N. Soroka F., E. Kunder V., A. Eremeeva V., E. Chernyaeva V., R. Ivanov A., P. Pukhtinskaya S., А. Лила М., В. Мазуров И., Е. Зонова В., О. Несмеянова Б., Т. Плаксина В., Д. Кречикова Г., О. Решетько В., Л. Денисов Н., И. Гордеев Г., Т. Покровская Г., О. Антипова В., Т. Кропотина В., Т. Поварова В., П. Шестерня А., Е. Ушакова Н., Н. Сорока Ф., Е. Кундер В., А. Еремеева В., Е. Черняева В., Р. Иванов А., П. Пухтинская С.

المصدر: Rheumatology Science and Practice; Vol 56, No 3 (2018); 293-301 ; Научно-практическая ревматология; Vol 56, No 3 (2018); 293-301 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20183

مصطلحات موضوعية: ankylosing spondylitis, infliximab (Remicade®), biosimilar, BCD-055, анкилозирующий спондилит, инфликсимаб (ремикейд), биоаналог

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2562/1709; Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi:10.14412/1995- 4484-2015-657-660; Дубинина ТВ, Гайдукова ИЗ, Годзенко АА и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно-практическая ревматология. 2017;55(4):344-50 [Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):344-50 (In Russ.)]. doi:10.14412/1995-4484-2017-344-350; Эрдес ШФ, Дубинина ТВ, Абдулганиева ДЭ и др. Клиническая характеристика анкилозирующего спондилита в реальной практике в России: результаты одномоментного многоцентрового неинтервенционного исследования ЭПИКА2. Научно-практическая ревматология. 2016;54(Прил 1):10-4 [Erdes ShF, Dubinina TV, Abdulganieva DE, et al. Clinical characteristics of ankylosing spondylitis in real practice in Russia: Results of the cross-sectional non-interventional trial EPICA2. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):10-4 (In Russ.)]. doi:10.14412/1995-4484-2016-1S-10-14; Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global Prevalence of Spondyloarthritis: A systematic review and metaregression analysis. Arthritis Care Res. 2016;68:1320-31. doi:10.1002/acr.22831.; Van der Heijde D, Ramiro S, Landewe R. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi:10.1136/annrheumdis-2016-210770; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].; Ward MM, Deodhar A, Akl EA. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheum. 2016 Feb;68(2):282-98. doi:10.1002/art.39298; Каратеев ДЕ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная эффективность и безопасность биоаналога инфликсимаба (BCD-055) и оригинального инфликсимаба у пациентов с анкилозирующим спондилитом (результаты международных многоцентровых рандомизированных двойных слепых клинических исследований I и III фазы). Современная ревматология. 2017;11(3):14-25 [Karateev DE, Mazurov VI, Zonova EV, et al. Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(3):14-25 (In Russ.)]. doi: 10/14412/1996-7012-2017-3; Gamez-Belmonte R, Hernandez-Chirlaque C, ArredondoAmador M. Biosimilars: concepts and controversies. Pharmacol Res. 2018 Feb 8. pii: S1043-6618(17)31164-7. doi:10.1016/j.phrs.2018.01.024 [Epub ahead of print]. Review.; WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs), annex 2. World Health Organ Tech Rep Ser. 2013;977:53-89.; European Medicines Agency. Biosimilar Medicines. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/special_topics/document_listing/document_listing_000318.jsp. Accessed 20 February 2018; European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev1. 2014.; U.S. Food and Drug Administration. Biosimilars. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm. Accessed 20 February 2018.; Насонов ЕЛ. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016;54(6):628-40 [Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.)]. doi:10.14412/1995-4484-2016-628-640; Федеральный закон от 22 декабря 2014 г. № 429-ФЗ «О внесении изменений в Федеральный закон "Об обращении лекарственных средств"». Принят Государственной Думой 9 декабря 2014 г. Одобрен Советом Федерации 17 декабря 2014 г. [Federal law of December 22, 2014 № 429-FZ «On Amendments to the Federal Law "On Circulation of Medicines"». Adopted by the State Duma on December 9, 2014 Approved by the Federation Council December 17, 2014 (In Russ.)].; Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017 Apr;77(6):671-7. doi:10.1007/s40265-017-0717-1; Generics and Biosimilars Initiative. Biosimilars approved in Europe. [February 24, 2017]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilarsapproved-in-Europe; Hung A, Vu Q, Mostovoy L. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? J Manag Care Spec Pharm. 2017;23(12):1234-44. doi:10.18553/jmcp.2017.23.12.1234; Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2017;0:1-10. doi:10.1136/annrheumdis-2017-211937; Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003 Aug; 48(8):2224-33. doi:10.1002/art.11104; Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb;52(2):582-91. doi:10.1002/art.20852; Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013 Oct;72(10):1605-12. doi:10.1136/annrheumdis-2012-203091. Epub 2013 May 16.; Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016 Jan 20;18:25. doi:10.1186/s13075-016-0930-4; Park W, Yoo DH, Miranda P, et al Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017 Feb;76(2):346-54. doi:10.1136/annrheumdis-2015-208783. Epub 2016 Apr 26.; Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009 Feb;68(2):209-15. doi:10.1136/ard.2007.087288. Epub 2008 Apr 2.; Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012 SepOct;30(5):700-6. Epub 2012 Oct 17.; Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012 Nov;67(5):e179-85. doi:10.1016/j.jaad.2011.05.038. Epub 2011 Jul 14.; Toussirot E, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. doi:10.1136/rmdopen-2015-000239; Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009 Jul;48(7):716-20. doi:10.1093/rheumatology/kep080. Epub 2009 May 4.; Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases. Medicine (Baltimore). 2007 Jul;86(4):242-51. doi:10.1097/MD.0b013e3181441a68; Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. AntiTumor Necrosis Factor-α Induced Systemic Lupus Erythematosus. Open Rheumatol J. 2012;6:315-9. doi:10.2174/1874312901206010315. Epub 2012 Nov 16.; Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002 May 1;168(9):4620-7. doi:10.4049/jimmunol.168.9.4620; Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-a biological therapy: From bench to bedside. J Microbiol Immunol Infect. 2014 Aug;47(4):268-74. doi:10.1016/j.jmii.2013.03.005. Epub 2013 May 30.; Каратеев ДЕ. Вопросы иммуногенности биологических препаратов: теория и практика. Современная ревматология. 2009;3(1):67-72 [Karateev DE. The problems of the immunogenicity of biologicals: theory and practice. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2009;3(1):67-72 (In Russ.)]. doi:10.14412/1996-7012-2009-527; Eng GP, Bentzen K, Bliddal H, et al. Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study. Arthritis. 2015;2015:784825. doi:10.1155/2015/784825. Epub 2015 Feb 11.; Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014 Apr;170(4):922-9. doi:10.1111/bjd.12791; Aikawa NE, de Carvalho JF, Almeida Silva CA, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi:10.1007/s12016-009-8140-3; https://rsp.mediar-press.net/rsp/article/view/2562

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2562
https://doi.org/10.14412/1995-4484-2018-293-301

المؤلفون: E. Nasonov L., V. Mazurov I., E. Zonova V., L. Knyazeva A., I. Marusenko M., O. Nesmeyanova B., T. Plaksina V., Yu. Shapovalova S., E. Ilivanova P., D. Krechikova G., N. Petrochenkova A., O. Reshetko V., L. Denisov N., I. Gordeev G., A. Davydova F., N. Eremina A., E. Zemerova V., T. Ivanova B., A. Kastanayan A., T. Pokrovskaya G., S. Smakotina A., E. Smolyarchuk A., A. Artemyeva V., R. Ivanov A., Yu. Usacheva V., E. Chernyaeva V., Е. Насонов Л., В. Мазуров И., Е. Зонова В., Л. Князева А., И. Марусенко М., О. Несмеянова Б., Т. Плаксина В., Ю. Шаповалова С., Е. Иливанова П., Д. Кречикова Г., Н. Петроченкова А., О. Решетько В., Л. Денисов Н., И. Гордеев Г., А. Давыдова Ф., Н. Еремина А., Е. Земерова В., Т. Иванова Б., А. Кастанаян А., Т. Покровская Г., С. Смакотина А., Е. Смолярчук А., А. Артемьева В., Р. Иванов А., Ю. Усачева В., Е. Черняева В.

المصدر: Rheumatology Science and Practice; Vol 55, No 4 (2017); 351-359 ; Научно-практическая ревматология; Vol 55, No 4 (2017); 351-359 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20174

مصطلحات موضوعية: rheumatoid arthritis, rituximab, Acellbia®, MabThera®, ревматоидный артрит, ритуксимаб, Ацеллбия®, Мабтера®

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2407/1595; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР- Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidance]. Moscow: GEOTAR-Media; 2008. P. 290-331].; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi:10.1016/S0140-6736(16)30173-8; Catrina AI, Svensson CI, Malmström V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol. 2017;13(2):79-86. doi:10.1038/nrrheum.2016.200; Moura RA, Fonseca JE. To B or not to B the conductor of rheumatoid orchestra. Clin Rev Allerg Immunol. 2012 Dec;43(3):281-91. doi:10.1007/s12016-012-8318-y; Leandro M. B cells and rheumatoid factors in autoimmunity. Int J Rheum Dis. 2015;18:379-81. doi:10.1111/1756-185X.12690; Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016;213:1937-50. doi:10.1084/jem.20160792; Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017 Jun;39(4):437-46. doi:10.1007/s00281-017-0627-z; Bugatti S, Bogliolo L, Montecucco C, Manzo A. B cell autoimmunity and bone damage in rheumatoid arthritis. Reumatismo. 2016;68(3):117-125. doi:10.4081/reumatismo.2016.914.; Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20. Blood. 1994;83:435-45.; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с. [Nasonov EL, editor. Genno- inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p.].; Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheum Ther. 2015;2:99-111. doi:10.1007/s40744-015-0016-9; Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 55-93 [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Moscow: IMA-PRESS; 2012. P. 55-93].; Bugatti S, Vitolo B, Caporali R, et al. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int. 2014;2014:681678. doi:10.1155/2014/681678; Seyfizadeh N, Seyfizadex N, Hasenkamp J, Huerta-Yepez S. A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Clin Rev Oncol Hematol. 2016;97:275-90. doi:10.1016/j.critrevonc.2015.09.001; De Lemos LLP, de Oliveira Costa J, de Avila Machado MA, et al. Rituximab for rheumatoid arthritis treatment: a systemic review. Rev Bras Reumatol. 2014;54:220-30. doi:10.1016/j.rbr.2013.08.001; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356. doi:10.1002/14651858.CD007356.pub2; Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-36. doi:10.1136/annrheumdis-2016-210708; Keyser FD, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry. J Rheumatol. 2014;41:1761-5. doi:10.3899/jrheum.131279; Harrold LR, Reed GW, Shewade A, et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol. 2015;42:1090-8. doi:10.3899/jrheum.141043; Wendler J, Burmester GR, Sö rensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non- interventional study in 2,484 patients. Arthritis Res Ther. 2014;16:R80. doi:10.1186/ar4521; Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi:10.1186/s13075-016-0951-z; Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi:10.1136/annrheumdis-2016-210715; Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1-26. doi:10.1002/art.39489; Насонов ЕЛ, Каратеев ДЕ. Ревматоидный артрит. В кн.: Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 17-57 [Nasonov EL, Karateev DE. Rheumatoid arthritis. In: Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. P. 17-57].; Насонов ЕЛ, Зонова ЕВ, Иванова ОН и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-9 [Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.)]. doi:10.14412/1995-4484-2016-510-519; Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131. doi:10.1186/ar2798; Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377-86. doi:10.1002/art.22019; Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi:10.1002/art.30152; Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab; mechanisms of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917-25. doi:10.1136/ard.2007.080960; Bredemeier M, de Oliveira FK, Rocha CM. Low-versus High-dose rituximab for rheumatoid arthritis: a systemic review and metaanalysis. Arthritis Care Res. 2014;66:228-35. doi:10.1002/acr.22116; Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi:10.1136/ard.2010.144998; Sacco JJ, Botten J, Macbeth F, et al. The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLoS ONE. 2010; 5(1):e8933. doi:10.1371/journal.pone.0008933; Van Vollenhoven RF. More or less rituximab? Biology and clinic, regulators and researchers. Arthritis Rheum. 2011;63:594-6. doi:10.1002/art.30154; Ferraccioli GF, Tolusso B, Gremese E. Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros anc cons? Arthritis Re Ther. 2016;18:126. doi:10.1186/s13075-016-1022-1; Porter D, van Melckebeke J, Dale J. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open- label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239-47. doi:10.1016/S0140-6736(16)00380-9; Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo- controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi:10.1002/art.21778; Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.; Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (D A N C E R) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.; Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE). Ann Rheum Dis. 2010;69:1629-35. doi:10.1136/ard.2009.119933; Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.; Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi:10.1136/ard.2010.137703; Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.; Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi:10.1002/acr.20419; Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi:10.1136/annrheumdis-2011-200170; Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi:10.1093/rheumatology/keq116; Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double- blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi:10.1136/annrheumdis-2014-206015; Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.; Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi:10.1093/rheumatology/kep155; Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi:10.1136/annrheumdis-2013-203480;63; McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi:10.1093/rheumatology/ken103; Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi:10.2217/ijr.14.18; Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi:10.1002/art.30427; Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi:10.1016/j.jbspin.2011.12.004; Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi:10.4103/ijdvl.IJDVL_1078_14; Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi:10.1111/ajd.12571; Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi:10.1093/ndt/gfw251; Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to lowdose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi:10.1111/ejh.12199; Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low- dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi:10.1111/ejh.12102; Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi:10.1093/rheumatology/ker176; Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi:10.1136/annrheumdis-2012-201956; Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi:10.1002/art.23059; Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi:10.1136/ard.2009.109041; Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17:134. doi:10.1186/s13075-015-0630-5; Quartuccio L, di Bidino R, Ruggeri M, et al. Cost-effectiveness analysis of two rituximab retreatment regimens for longstandinf rheumatoid arthritis. Arthritis Care Res. 2015;67:947-55. doi:10.1002/arc22535; Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80. doi:10.1136/ard.2010.148759; Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72:329-36. doi:10.1136/annrheumdis-2011-201117; Sneller MC, Zonghui H, Langford CA, et al. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42. doi:10.1002/art.34322; De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-8. doi:10.1002/art.34331; Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-3. doi:10.1136/ard.2002.004929; Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48-55. doi:10.1016/j.autrev.2011.07.005; Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease- associated interstitial lung disease. Rheumatology (Oxford). 2016;55(7):1318-24. doi:10.1093/rheumatology/kew195; Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017 Apr 24;56(8):1348-57. doi:10.1093/rheumatology/kex072; https://rsp.mediar-press.net/rsp/article/view/2407

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2407
https://doi.org/10.14412/1995-4484-2017-351-359